Stelara (Ustekinumab) Market Forecast 2025-2034: Analysing Major Trends, Opportunities, and Growth Drivers

How Are the key drivers contributing to the expansion of the stelara (ustekinumab) market?
An increase in the number of psoriasis patients, characterized by an autoimmune disorder leading to quick skin cell turnover and red, scaly patches, is projected to drive the stelara (ustekinumab) market's expansion. The escalating incidence of psoriasis patients can be traced back to reasons such as better diagnosis methods, environmental factors, genetic inclination, and an aging demographic. Stelara (ustekinumab) is designed to suppress interleukin-12 and interleukin-23. It assists psoriasis patients by efficiently mitigating inflammation and the formation of plaque, subsequently bringing about superior skin clearance and the management of long-standing symptoms, thus enriching their quality of life. For example, the National Library of Medicine, a medical library based in the US, released a report in May 2024 stating that the prevalence of psoriasis had risen to 0.221% in 2022, with a total of 6,930 PsA instances reported among a 3,133,500 population. Hence, we can conclude that the increase in psoriasis patients' prevalence is forecasted to propel the stelara (ustekinumab) market's growth.

Get Your Stelara (Ustekinumab) Market Report Here:
https://www.thebusinessresearchcompany.com/report/stelara-ustekinumab-global-market-report-

What growth opportunities are expected to drive the stelara (ustekinumab) market's CAGR through 2034?
In recent times, the market size for Stelara (ustekinumab) has significantly expanded. The forecast for growth projects it to increase from $11,177.34 million in 2024 to $11,850.79 million in 2025, sporting a compound annual growth rate (CAGR) of 6.0%. The spike in growth over the historic period can be traced back to factors like increased healthcare expenditure, development of specialty pharmaceutical distribution channels, an expanded scope of clinical trial programs, greater investment in research and development, as well as the escalating usage of telemedicine as a channel for improving treatment accessibility.

Strong expansion is predicted in the upcoming years for the Stelara (ustekinumab) market. By 2029, the market size is set to expand to $14,768.48 million with a compound annual growth rate (CAGR) of 5.7%. This projected growth during the forecast period can be attributed to several factors such as the broadening indications for Stelara, the increasing occurrence of autoimmune diseases, the high success rate in refractory cases versus alternate options, escalating awareness amongst patients and healthcare providers, and the heightened emphasis on personalized medicine. Key trends expected in the forecast period encompass the adoption of biologic therapies, the creation of superior drug delivery systems, the emergence of data-driven healthcare systems, collaborations and licensing deals amongst pharmaceutical entities, and advancements in biologics production technology.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19935&type=smp

What are the emerging trends shaping the future of the stelara (ustekinumab) market?
The primary trend observed in the Stelara (Ustekinumab) market revolves around the creation of innovative products, specifically Stelara biosimilars, which offer a cost-effective treatment solution for patients with chronic inflammatory diseases. These biosimilars, mirroring the medicinal action of the biological drug Stelara (Ustekinumab), target IL-12 and IL-23 and are used in the treatment of autoimmune disorders such as psoriasis and psoriatic arthritis. Importantly, in October 2024, Accord BioPharma Inc., an American biopharmaceutical organization, disclosed that the U.S. Food and Drug Administration (FDA) had sanctioned IMULDOSA (ustekinumab-srlf), a biosimilar to Johnson & Johnson's Stelara (ustekinumab). IMULDOSA distinguishes itself with its wide-ranging indications for treatment, which include adults with moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn's disease, and ulcerative colitis. Uniquely, it is also approved for pediatric patients aged 6 and above suffering from moderate to severe plaque psoriasis and active psoriatic arthritis, making it a diverse treatment option. Owing to this expansive coverage, IMULDOSA positions itself as a potent solution for managing various immune-mediated inflammatory disorders.

Which growth-oriented segments of the stelara (ustekinumab) market are leading the industry's development?
The stelara (ustekinumab)market covered in this report is segmented -

1) By Indication: Plaque Psoriasis; Psoriatic Arthritis; Crohn's Disease; Ulcerative Colitis; Other Indications
2) By Route Of Administration: Subcutaneous Injection; Intravenous Infusion
3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
4) By End User: Pediatric; Adult; Geriatric

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/Discount?id=19935&type=discount

What regions are leading the charge in the stelara (ustekinumab) market?
North America was the largest region in the stelara (ustekinumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stelara (ustekinumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What companies are at the forefront of innovation in the stelara (ustekinumab) market?
Major companies operating in the stelara (ustekinumab) market include Johnson & Johnson

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=19935&type=smp

What Is Covered In The Stelara (Ustekinumab) Global Market Report?

•Market Size Forecast: Examine the stelara (ustekinumab) market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the stelara (ustekinumab) market for a structured understanding.
•Key Players Overview: Analyze major players in the stelara (ustekinumab) market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the stelara (ustekinumab) market.
•Segment Contributions: Evaluate how different segments drive overall growth in the stelara (ustekinumab) market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the stelara (ustekinumab) market.
•Industry Challenges: Identify potential risks and obstacles affecting the stelara (ustekinumab) market.
•Competitive Landscape: Review strategic developments in the stelara (ustekinumab) market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.